Clinical Trial Search

Primary: Maximum Observed Plasma Concentration (Cmax) of Talazoparib — 8.4 nanogram per milliliter (ng/mL)

Primary: Number of Subjects Reporting Solicited Local Symptoms — 1; 0; 2; 0 Participants

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants

Primary: Area Under the Plasma Concentration-time Curve (AUC) From Dosing to Time of Last Measurable Concentration (AUC0-last) of Uprifosbuvir (MK-3682) — 8.55; 4.23 uM*hr

Primary: Number of Participants With Wound Closure of the Treatment Sites at Three Months — 29; 29 Participants

Primary: Reduction in Mean Number of Days of Cannabis Use Per Week — 4.1; 3.1 days of use per week

Primary: Safety and Tolerability of AZD7986 by Assessment of the Number of Adverse Events (AEs) Following Administration of Oral Solution in Single Ascending Dose (SAD - Part 1a…

Primary: Mass Balance of Total Radioactivity in Urine — 68.97 Cumulative percent excreted (%)

Primary: Incidence Rate of DLT Within the First Two Cycles of LDE225 (Sonidegib) in Combination With Docetaxel — 0; 0; 0 Participants

Primary: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Evacetrapib — 983; 1170; 1120 nangram/milliliter (ng/mL)

Primary: Change From Baseline in Plasma HIV-1 RNA at 168 Hours Post-Dose — -1.67; -1.35; -1.60; -1.30 log10 copies/mL

Primary: Area Under the Concentration Time-curve From Hour 0 to 24 Hours (AUC0-24hr) of MK-8892 at Day 1 and Day 28 — 0.143; 0.123; 0.192; 0.863 μM*hr

Primary: Number of Subjects Reporting Adverse Events — 13 Participants

Primary: Comparison of Areas Under the Curve (AUC) to the Last Time With a Concentration ≥ LLOQ [AUC0-t] and to Infinity [AUCinf] — 2,313; 2,098; 2,469; 2,175 hr x ng/mL

Primary: Peak Plasma 2-AAA Concentration Percentage Change From Baseline — 63.4 Percentage Change